Capricorn Fund Managers Ltd Buys 82,944 Shares of Phibro Animal Health Corporation $PAHC

Capricorn Fund Managers Ltd raised its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 45.1% in the first quarter, HoldingsChannel.com reports. The firm owned 267,045 shares of the company’s stock after purchasing an additional 82,944 shares during the quarter. Phibro Animal Health accounts for approximately 2.3% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 13th biggest holding. Capricorn Fund Managers Ltd’s holdings in Phibro Animal Health were worth $14,770,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. lifted its position in shares of Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after purchasing an additional 295 shares during the period. Tudor Investment Corp ET AL raised its stake in Phibro Animal Health by 3.4% during the third quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock worth $412,000 after buying an additional 338 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after buying an additional 363 shares during the period. Farther Finance Advisors LLC lifted its holdings in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after buying an additional 386 shares during the period. Finally, Brooklyn Investment Group boosted its position in Phibro Animal Health by 8.7% during the fourth quarter. Brooklyn Investment Group now owns 6,757 shares of the company’s stock valued at $255,000 after acquiring an additional 538 shares during the last quarter. Institutional investors own 99.34% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on PAHC. Citigroup lowered their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Weiss Ratings cut Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, June 15th. Finally, Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $42.50.

Insiders Place Their Bets

In related news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $55.80, for a total transaction of $392,832.00. Following the transaction, the chief executive officer directly owned 67,720 shares of the company’s stock, valued at approximately $3,778,776. This represents a 9.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 46,768 shares of company stock worth $2,560,222. 50.13% of the stock is currently owned by corporate insiders.

Phibro Animal Health Stock Down 1.3%

Shares of NASDAQ PAHC opened at $31.40 on Wednesday. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The firm has a market cap of $1.27 billion, a PE ratio of 13.48, a P/E/G ratio of 0.48 and a beta of 0.46. The company’s fifty day simple moving average is $37.81 and its 200 day simple moving average is $43.97. Phibro Animal Health Corporation has a 12-month low of $25.34 and a 12-month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The firm had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, sell-side analysts forecast that Phibro Animal Health Corporation will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd were given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date of this dividend was Wednesday, June 3rd. Phibro Animal Health’s payout ratio is presently 20.60%.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.